Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237111 | 0.89 | MCHR1 (0.41) | MCHR1PKMTAS1R3TAS1R1FGFR1 | |
| SCHEMBL4226943 | 0.86 | ACHE (0.35) | MCHR1ACHE | |
| SCHEMBL4233732 | 0.84 | MCHR1 (0.35) | MCHR1PKMTAS1R3TAS1R1FGFR1 | |
| SCHEMBL4229108 | 0.84 | MCHR1 (0.36) | MCHR1PKMTAS1R3TAS1R1ACHE | |
| SCHEMBL4233730 | 0.84 | KCNH2 (0.36) | ACHEMAPT | |
| SCHEMBL4241978 | 0.83 | PKM (0.36) | MCHR1PKMTAS1R3TAS1R1FGFR1 | |
| SCHEMBL4233531 | 0.81 | MCHR1 (0.44) | MCHR1PKMTAS1R3TAS1R1FGFR1 | |
| SCHEMBL4237948 | 0.81 | MCHR1 (0.34) | MCHR1PKMTAS1R3TAS1R1FGFR1 | |
| SCHEMBL4240029 | 0.81 | MCHR1 (0.43) | MCHR1PKMTAS1R3TAS1R1FGFR1 | |
| SCHEMBL4229231 | 0.80 | MCHR1 (0.43) | MCHR1PKMTAS1R3TAS1R1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MCHR1 47/4885PKM 1734/4885TAS1R3 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.